2026 SITC EU Immuno-Oncology
Drug Development Summit

Sept. 3–4, 2026 in Lausanne, Switzerland at the Agora Cancer Research Center

Register Now

Register NowBrowse ScheduleView OrganizersRegistration RatesHotel Info

Thank you to our partners. 

Collaborative Partner

Marketing Partner

Marketing Partner

The 2026 EU Immuno-Oncology Drug Development Summit will educate and engage the European IO community on the next wave of IO therapeutics and ensure that active, innovative, new therapies are rapidly and appropriately moved into clinical testing.

Organizers

Madiha Derouazi, PhD
Swiss Biotech Association 

Ivan Diaz-Padilla, MD, PhD
Ipsen

Pedro Romero, MD

Pedro Romero, MD
Novigenix

Michael Stumpp, PhD
Molecular Partners AG

Zhen Su, MD, MBA
Marengo Therapeutics

Schedule

Sept. 3–4, 2026 in Lausanne, Switzerland at the Agora Cancer Research Center, Rue du Bugnon 25A, CH-1011 Lausanne

Please note that the schedule is subject to change.

Day 1 — Thursday, September 3, 2026

8:00–8:05 a.m.

Opening Remarks

8:05–8:55 a.m.

Keynote Address: Intersection of IO and Autoimmunity

E. John Wherry, PhD – University of Pennsylvania

Session I: Beyond PD-1 8:55–10:25 a.m.

8:55–9:15 a.m.

Modality Update: Perspectives, Challenges, and Opportunities

Antoine Italiano, MD, PhD – Gustave Roussy

9:15–9:35 a.m.

Vaccines

Lisa H. Butterfield, PhD – Independent Consultant

9:35–9:55 a.m.

Multi-/Bi-specific Antibodies

Cedrik M. Britten, MD – Immatics Biotechnologies

9:55–10:25 a.m.

Panel Discussion

Moderator: Zhen Su, MD, MBA – Marengo Therapeutics

  • Arati V Rao, MD – Pfizer Inc.
  • Pablo Umana, MD – Biotech Start-up, Switzerland
  • Ilhan Celik, MD – BioNTech
10:25–10:40 a.m.

Break

Session II: Autoimmunity and Oncology 10:40 a.m.–12:10 p.m.

10:40–11:00 a.m.

Immune Cell Engager (including T-Cell Engagers)

Anna Farago, MD, PhD – Amgen

11:00–11:20 a.m.

CAR T

Denis Migliorini, MD – University of Geneva

11:20–11:40 a.m.

Role of Regulatory T Cells (Tregs)

To be announced

11:40 a.m.–12:10 p.m.

Panel Discussion w/ Investor Perspective

Moderator: Beverly Lu, PhD – Yosemite

  • Anne Kerber, MD – BMS
  • Jackson Egen, PhD – Gilead Sciences
  • Additional panelists to be announced
12:10–1:10 p.m.

Lunch

Session III: Novel Modality – Antibody-drug Conjugates 1:10–2:40 p.m.

1:10–1:30 p.m.

B7-H3

Solange Peters, MD, PhD – Lausanne University Hospital

1:30–1:50 p.m.

Immune Payload

Michael Alonso, PhD – Bolt Biotherapeutics

1:50–2:10 p.m.

ADC – IO Combination

Ignacio Duran, MD, PhD – University Hospital “Marqués de Valdecilla”

2:10–2:40 p.m.

Panel Discussion

Moderator: Ivan Diaz-Padilla, MD, PhD – Ipsen

  • Aurelien Marabelle, MD, PhD – Gustave Roussy
  • Claire Friedman, MD – Eli Lilly
  • Solange Peters, MD, PhD – Lausanne University Hospital
2:40–2:55 p.m.

Break

Session IV: Regulatory Considerations — Paving the Way for Innovation 2:55–4:35 p.m.

2:55–3:55 p.m.

Panel Discussion: Global Regulatory Perspectives & Clinical Trial Design

Moderator: Michael Stumpp, PhD – Molecular Partners

  • Hilke Zander MSC, MDRA – Paul Ehrlich Institute
  • Erin Larkins, MD – Food and Drug Administration (FDA)
  • Antoine Italiano, MD, PhD – Gustave Roussy
  • Richard Baird, MD, PhD – Cambridge Cancer Center
  • Elena Garralda, MD PhD – Molecular Cancer Therapy Research Unit (UITM)
3:55–4:35 p.m.

Panel Discussion: Pre-Clinical Models

Moderator: Pedro Romero, MD – Novigenix

  • Ekaterine Asatiani, MD – Incyte
  • Chinatsu Sakata-Sakurai, PharmD – Astellas Pharma
  • Jackson Egen, PhD – Gilead Sciences
  • Jan Lichtenberg, PhD – InSphero
4:35 p.m.

Closing Remarks

4:35–5:30 p.m.

Networking Reception

Day 2 — Friday, September 4, 2026

8:00–8:05 a.m.

Opening Remarks

Session V: Next Wave IO Platforms 8:05–8:45 a.m.

8:05–8:45 a.m.

Panel Discussion: Next Wave IO Platforms

Moderator: Zhen Su, MD, MBA – Marengo Therapeutics

  • Jackson Egen, PhD – Gilead Sciences
  • Chinatsu Sakata-Sakurai, PharmD – Astellas Pharma
  • Anna Farago, MD, PhD – Amgen
  • Christian Klein, PhD – Biotech start-up

Session VI: Next Wave Combination Therapy 8:45–10:15 a.m.

8:45–9:05 a.m.

Radioimmunotherapy

Ken Herrmann, MD, MBA – Universitätsklinikum Essen

9:05–9:25 a.m.

Biomarkers in Radioimmunotherapy

Pedro Romero, MD – Novigenix

9:25–9:45 a.m.

Immunogenic Cell Death

Guido Kroemer, MD, PhD – University of Paris Descartes

9:45–10:15 a.m.

Panel Discussion

Moderator: Michael Stumpp, PhD – Molecular Partners

  • Anne Kerber, MD – Bristol Myers Squibb
  • Arati V Rao, MD – Pfizer Inc.
  • George Coukos, MD, PhD – Ludwig Institute for Cancer Research
10:15–10:30 a.m.

Break

Session VII: Investment Panel 10:30–11:25 a.m.

10:30–11:25 a.m.

Panel Discussion: Biotech Innovation in Europe and its Partnership with the US

Moderator: Zhen Su, MD, MBA – Marengo Therapeutics

  • Beverly Lu, PhD – Yosemite
  • Max Klement, PhD – Novo Holdings
  • Joern-Peter Halle, PhD – BVG
  • Jasper Bos, PhD – Forbion
  • Francesco De Rubertis, PhD – Medicxi
11:25–11:30 a.m.

Closing Remarks

Program Description

The 2026 EU Immuno-Oncology Drug Development Summit will educate and engage the European IO community on the next wave of IO therapeutics and ensure that active, innovative, new therapies are rapidly and appropriately moved into clinical testing.

The program will be a key forum for continuing exploration and discussion of best practices for modern IO drug development, including study design, regulatory pathways and emerging technologies.

Target Audience

The target audience for this program is investors and physicians and scientists in academia, industry (including emerging biotech companies), and regulatory agencies in the US and Europe who have an interest in the strategic, preclinical, clinical and regulatory aspects of efficient IO drug development.

Learning Objectives

Understand Optimal Clinical Trial Design

Understand optimal clinical trial design specific to immuno-oncology therapeutics (including trial designs, dose-finding, and endpoints) that reflect regulatory expectations and requirements.

Integrate Objectives

Integrate scientific and regulatory objectives to develop preclinical and clinical strategies that drive efficient development of immuno-oncology therapeutics.

Foster International Relationships

Foster international relationships between regulatory agencies, industry/biotech members, and academic investigators in Europe and the US to develop effective strategies for the development of immuno-oncology therapeutics through discussion of case studies, lessons learned and looking ahead across mechanisms (including deeper dives into immune cell engagers, cell therapies and AI for IO drug development).

Describe Key Resources

Describe key informational resources and implement best practices regarding the development of immuno-oncology therapeutics across treatments beyond PD-I (Multi-/Bi-specific Antibodies), novel modalities (Antibody-drug Conjugates (ADCs)), and next-wave combination therapies (Radioimmunotherapy, Immunogenic Cell Death targets, Oncolytic Virus, etc).

Registration Rates

Early Rates
Ends Aug. 4 at 11:59 pm		 Regular
Ends Aug. 28 at 11:59 pm		 Onsite
Member – Regular $450 $650 $700
Member – Industry $1,320 $1,520 $1,570
Member – Student $225 $425 $475
NM – Regular $720 $920 $970
NM – Industry $1,650 $1,850 $1,900
NM – Student $350 $550 $600

Hotel Options

Please be advised that SITC does not have a hotel block of rooms available for the program. As such, attendees will be responsible for booking their own accommodations. For reference, please find a list of suggested hotels in the Lausanne area within reasonable distance of the AGORA Cancer Research Center: 

  • Hotel Carlton Lausanne - Avenue de Cour 4, 1007 Lausanne
  • Hotel Royal Savoy and Spa - Avenue d'Ouchy 40, 1006 Lausanne
  • Hotel des Patients CHUV - Avenue de la Sallaz 8 , 1005 CH Lausanne
  • Lausanne Palace - Rue du Grand-Chêne 7-9, 1003 Lausanne
  • Hotel Beau Rivage - Chemin de Beau-Rivage 21, 1006 Lausanne
  • Hotel D'Angleterre - Pl. du Port 11, 1006 Lausanne